Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

IGI-AbbVie-Announces

More Like This

IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma

Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma

PR Newswire associated0

Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma

IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer

PR Newswire associated0

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model

PR Newswire associated0

ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery